• 1
    Faderl S, Kantarjian H. Novel therapies for myelodysplastic syndromes. Cancer. 2004; 101: 226241.
  • 2
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 20792088.
  • 3
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 24292440.
  • 4
    Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794803.
  • 5
    Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006; 106: 10991109.
  • 6
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549557.
  • 7
    List AF, Dewald G, Bennett J, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study [Abstract 5]. J Clin Oncol. 2005; 23: 2s.
  • 8
    Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003; 102: 23792386.
  • 9
    Feldman EJ, Seiter KP, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996; 10: 4042.
  • 10
    Onida F, Kantarjian H, Smith T, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99: 840849.
  • 11
    Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003; 2: 202208.
  • 12
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 38353849.
  • 13
    Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996; 88: 24732479.
  • 14
    Beran M, O'Brien S, Thomas D, et al. Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res. 2003; 9: 40844091.
  • 15
    Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999; 17: 28192830.
  • 16
    Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21: 46424649.
  • 17
    Cheson BD, Greenberg PL, M. Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419425.
  • 18
    Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res. 1991; 193: 2735.
  • 19
    Seiter K, Liu D, Feldman EJ, et al. Intravenous bolus topotecan in patients with myelodysplastic syndrome. Leuk Lymphoma. 2001; 42: 963968.
  • 20
    Klein CE, Kastrissios H, Miller AA, et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006; 57: 199206.